New hope for aggressive breast cancer: immune-boosting drug combo tested
NCT ID NCT06175390
First seen Feb 06, 2026 · Last updated May 06, 2026 · Updated 13 times
Summary
This study tests whether adding the drug tiragolumab to standard chemotherapy and atezolizumab can help people with triple negative breast cancer. It includes two groups: those with early-stage cancer and those with advanced cancer that has spread. The goal is to see if the combination shrinks tumors or slows disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Curie
Paris, 92210, France
-
Institut Curie
Saint-Cloud, 92210, France
Conditions
Explore the condition pages connected to this study.